HCW Biologics (HCWB) vs Processa Pharmaceuticals (PCSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Processa Pharmaceuticals is the larger company by market cap ($3.6 million vs $3.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | PCSA |
|---|---|---|
| Share price | $1.58 | $1.28 |
| Market cap | $3.53M | $3.58M |
| 1-day change | +3.27% | -5.19% |
| EPS (TTM) | $-19.84 | $-4.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.57 | $11.08 |
| 52-week low | $1.50 | $1.04 |
| Distance from 52-week high | -94.27% | -88.44% |
| Analyst consensus | buy | — |
| Avg. price target upside | +2937.97% | — |
| Average volume | 376.23K | 224.03K |
| Shares outstanding | 2.24M | 2.79M |
| Employees | 35 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Processa Pharmaceuticals
PCSA stock →Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
HCWB vs PCSA FAQ
Which is bigger, HCW Biologics or Processa Pharmaceuticals?
Processa Pharmaceuticals (PCSA) is larger, with a market capitalization of $3.58M compared with $3.53M for HCW Biologics (HCWB).
Are HCW Biologics and Processa Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.